$0.34
−19.84%Oct 15, 2026, 22:45 UTC
Estrella Immunopharma, Inc. announced that the first patient in the STARLIGHT-1 dose-expansion phase tolerated two EB103 infusions of 5 × 10⁶ T cells/kg, given three weeks apart, well during the first month, with no treatment-related serious adverse events reported.
Source:Oct 14, 2026, 20:15 UTC
Estrella Immunopharma, Inc. announced that Intermountain Health Platte Valley Hospital LDS Hospital has been activated as the fifth clinical site for its ongoing STARLIGHT-1 Phase I/II trial of EB103 in patients with relapsed B-cell non-Hodgkin's lymphoma.
Source:Aug 11, 2026, 12:00 UTC
Estrella Immunopharma activated University Hospitals Cleveland Medical Center as the fourth clinical site for its Phase I/II STARLIGHT-1 trial of EB103 in B-cell non-Hodgkin's lymphoma.
Source:Aug 3, 2026, 12:00 UTC
Estrella Immunopharma activated Oregon Health & Science University as the third clinical site for its Phase I/II STARLIGHT-1 trial of EB103 in B-cell non-Hodgkin's lymphoma.
Source:Jul 24, 2026, 12:00 UTC
Estrella Immunopharma dosed the first patient in the dose-expansion phase of its STARLIGHT-1 clinical trial for EB103 therapy in advanced B-cell non-Hodgkin's lymphoma.
Source: